bluuebunny/crossref_metadata_2025_split huggingface dataset:
A long life's relationship: Archibald Geikie, Alexander Macmillan and his publishing house
Authors: Sanders A. J. 
Published: September 2018

Abstract

The relationship between Sir Archibald Geikie, his publisher Alexander Macmillan and Macmillan & Co began when Archibald was a young man of 23 and continued until his death in 1924. Correspondence and other sources reveal the development of an intimate relationship with Alexander, as well as others such as Norman Lockyer, editor of
Nature
from 1869 and responsible for Macmillan's science books. Archibald's relationship with Alexander was of mutual benefit and supportive, although this study shows that this was not without difficulties and some disagreement. It was a professional relationship, with both men wanting the best for their publications, but also a personal relationship as Alexander welcomed Archibald into his home. Through Alexander, Archibald widened his circle of acquaintances and met his wife, Anna Maria Alice Gabrielle Pignatel, and became linked in marriage when Alexander married her sister, Jeanne Barbe Emma. Through Macmillan's publications, Archibald gained an international audience as a communicator, pioneer historian of science and a successful writer of popular and readable textbooks.
How Song of Songs Became a Divine Love Song
Authors: Kaplan Jonathan , Wilson-Wright Aren M. 
Published: September 2018

Abstract
The origin of the interpretation of Song of Songs as a description of God’s relationship with God’s beloved community has been a persistent question in the work’s history of interpretation. Earlier scholarship has provided a number of possible solutions to this problem, none of them conclusive. This article offers another possible answer: the language and imagery of the Northwest Semitic combat myth in Song 8:6-7, which identifies love with Yhwh as the victorious divine warrior, triggers the work’s interpretation as a divine love song. This argument receives support from some of the earliest allusions to Song of Songs in Revelation, which interpret Song of Songs in the context of apocalyptic discourse that likewise draws heavily on the combat myth.
Bakhtinian Carnivalesque and Paul’s Foolish and Scandalous Gospel
Authors: Nygaard Mathias 
Published: September 2018

Abstract
In this article I read the Pauline gospel through the heuristic prism of Bakhtinian carnivalesque. Such a reading is legitimated by Paul’s acknowledgement that his gospel was a scandal to the Jews and a foolishness to the Greeks (1 Cor. 1.23). As a literary trope carnivalesque can be summarized according to the following points: (1) it entails an unhindered interaction between all people; (2) in it otherwise impermissible behaviour is accepted; (3) it is set towards a uniting of opposites; (4) it explores the sacrilegious; and (5) it constitutes a redefinition of the physical and the bodily. In my argument I show that these aspects are all present in the Pauline literature in various ways. Properly defined, Paul’s gospel is carnivalesque. Altogether, my reading serves as a reminder of some of the subversive aspects of his theological narrative. This further allows me to describe parts of his non-representative and apophatic anthropology.
Morphology and molecules say: Tanytarsus latens, sp. nov. from Finland (Diptera: Chironomidae)
Authors: GIŁKA WOJCIECH , PAASIVIRTA LAURI , GADAWSKI PIOTR , GRABOWSKI MICHAŁ 
Published: September 2018

Tanytarsus latens sp. nov. is described from Finland (Ostrobothnia borealis, Satakunta). Both morphological and molecular analyses indicate that T. latens belongs to the mendax species group. The adult male hypopygium of the new species resembles that of Tanytarsus occultus Brundin and of T. desertor Giłka et Paasivirta, while the molecular analysis based on the mitochondrial cytochrome oxidase (COI) gene fragment evidences that T. latens is a sister species to most of European Tanytarsus of the mendax group’s core, for which the COI barcodes are known. Notes on biology of T. latens are also provided.
Bilateral Transorbital and Transnasal Endoscopic Resection of a Frontal Sinus Osteoblastoma and Orbital Mucocele: A Case Report and Review of the Literature
Authors: Hicks Kelli L. , Moe Kris S. , Humphreys Ian M. 
Published: September 2018

Objective: Describe a novel treatment approach to a rare bony neoplasm in the frontal sinus. Study Design: Case report. Methods: Retrospective chart review of an osteoblastoma of the frontal sinuses complicated by a right orbital mucocle. Demographic, endoscopic, radiographic, pathologic, and surgical data were collected for synthesis and review. MEDLINE, Embase, and Cochrane databases were searched from 1977 to 2017 to review publications of surgical management of frontal sinus neoplasms. Results: A single female patient with a large frontal sinus osteoblastoma was successfully treated with a bilateral transorbital and transnasal approach. The right orbital mucocele was marsupialized into the frontal sinus. Gross total resection of the tumor was achieved, with complete resolution of the presurgical morbidity. The surgery was tolerated well without iatrogenic injury or sequela. Conclusion: Frontal sinus osteoblastoma is a rare condition. Complete surgical excision is considered curative. Various endoscopic and open approaches have been described. Here we show the feasibility and efficacy of a multiportal strategy in the successful management of a large frontal sinus osteoblastoma complicated by a right orbital mucocele.
Mycobacterial granuloma on the staple line after pulmonary resection
Authors: Matsuoka Katsunari , Ueda Mitsuhiro , Miyamoto Yoshihiro 
Published: September 2018

Objective It has been reported previously that granulomas can occur around nonabsorbable sutures, but that granuloma formation around the staple line is very rare. However, the increased use of thoracoscopic surgery is creating more opportunities to use automatic mechanical suturing equipment for pulmonary surgery, and it is expected that the incidence of granuloma around the staple line will increase. Methods We retrospectively investigated the clinical records of 6 patients who developed nontuberculous mycobacterial granuloma on the staple line after pulmonary resection. We investigated their clinical characteristics and compared them with data in 16 cases of cancer recurrence. Results Fluorodeoxyglucose uptake was detected in all 6 patients. Laboratory data including white blood cell counts and C-reactive protein levels were within normal ranges in all patients. There was no evident tendency in terms of age, sex, maximal standardized uptake value, or radiological findings. However, compared to cancer recurrence, mycobacterial granuloma around the staple line appeared after a longer period of time, and the proportion of patients who had a segmentectomy as the initial surgery was significantly higher. Conclusion When growing shadows are observed near the staple line, it is difficult to differentiate between cancer recurrence and nontuberculous mycobacterial granuloma from computed tomography and laboratory findings. However, if a mass shadow around the staple line appears 2, 3, or more years after segmentectomy, it could be considered likely to be a granuloma. “Post-segmentectomy” and “late occurrence” are important attributes for distinguishing staple line granuloma from cancer recurrence.
Exertional dyspnea after myocardial infarction: thinking beyond the diagnosis of heart failure
Authors: Koutsampasopoulos Konstantinos , Grigoriadis Savvas , Vogiatzis Ioannis 
Published: September 2018

Introduction We herein present an unusual case of a pseudoaneurysm of the left ventricular myocardium, which is a rare and fatal complication of myocardial infarction. Case report A 64-year-old man with a history of bipolar disorder and arterial hypertension was hospitalized for delayed presentation ST-elevation myocardial infarction. He was admitted to our hospital 24 hours after symptom onset. Diagnostic coronary angiography revealed 95% stenosis at the distal third of the right coronary artery, and he underwent a primary percutaneous coronary intervention to the culprit lesion. Despite administration of a diuretic and optimization of other pharmaceutical treatment, his heart failure deteriorated. Electrocardiography showed a sinus rhythm with Q-wave formation in the inferior wall leads (II, III, aVF), T-wave inversion in the same leads, and borderline QT prolongation (QTc of 490 ms). No ST elevation suggestive of left ventricular aneurysm formation was noticed. Forty days later, cardiac ultrasound revealed a dyskinetic cavity (pseudoaneurysm) in continuity with the posterior–inferior wall of the myocardium, resulting in severe mitral valve regurgitation. Unfortunately, the patient died while awaiting surgical treatment. Conclusion Although most patients with left ventricular pseudoaneurysm have a relatively benign outcome, those with symptoms of heart failure must be urgently diagnosed and treated.
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide
Authors: Schoch Laura K. , Cooke Kenneth R. , Wagner-Johnston Nina D. , Gojo Ivana , Swinnen Lode J. , Imus Philip , Fuchs Ephraim J. , Levis Mark , Ambinder Richard F. , Jones Richard J. , Gladstone Douglas E. 
Published: September 2018

Key Points
Checkpoint inhibition use before alloBMT followed by PTCy is not associated with increased aGvHD or transplant-related mortality/morbidity. Prior checkpoint inhibitor therapy should not be a contraindication to allogeneic transplantation, especially in the setting of PTCy.
The DNA repair transcriptome in severe COPD
Authors: Sauler Maor , Lamontagne Maxime , Finnemore Eric , Herazo-Maya Jose D. , Tedrow John , Zhang Xuchen , Morneau Julia E. , Sciurba Frank , Timens Wim , Paré Peter D. , Lee Patty J. , Kaminski Naftali , Bossé Yohan , Gomez Jose L. 
Published: September 2018

Inadequate DNA repair is implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the mechanisms that underlie inadequate DNA repair in COPD are poorly understood. We applied an integrative genomic approach to identify DNA repair genes and pathways associated with COPD severity.We measured the transcriptomic changes of 419 genes involved in DNA repair and DNA damage tolerance that occur with severe COPD in three independent cohorts (n=1129). Differentially expressed genes were confirmed with RNA sequencing and used for patient clustering. Clinical and genome-wide transcriptomic differences were assessed following cluster identification. We complemented this analysis by performing gene set enrichment analysis, Z-score and weighted gene correlation network analysis to identify transcriptomic patterns of DNA repair pathways associated with clinical measurements of COPD severity.We found 15 genes involved in DNA repair and DNA damage tolerance to be differentially expressed in severe COPD. K-means clustering of COPD cases based on this 15-gene signature identified three patient clusters with significant differences in clinical characteristics and global transcriptomic profiles. Increasing COPD severity was associated with downregulation of the nucleotide excision repair pathway.Systematic analysis of the lung tissue transcriptome of individuals with severe COPD identified DNA repair responses associated with disease severity that may underlie COPD pathogenesis.
Characteristics of patients expressing an interest in ketamine treatment: results of an online survey
Authors: Veraart Jolien K. E. , Smith-Apeldoorn Sanne Y. , Trueman Hayley , de Boer Marrit K. , Schoevers Robert A. , McShane Rupert 
Published: September 2018

BackgroundOff-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population. Little is known about which patients would seek ketamine treatment if it were more widely available.AimsTo explore some of the characteristics of the patients actively seeking ketamine treatment.MethodAn online survey containing questions about duration of current depressive episode, number of antidepressants used and other comments was completed by patients who were exploring the internet regarding the possibility of ketamine for depression.ResultsOf the 1088 people who registered their interest, 93.3% reported depression, 64.3% reported a chronic course of their symptoms and in the past 10 years, 86.3% had tried at least two antidepressants. Desperation was a common theme, but this appeared to be competently expressed. A small minority (<8%) reported experience of illegal ketamine use.ConclusionsIt cannot be ruled out that patients with different degrees of treatment resistance and comorbidities will seek treatment with ketamine. This stresses the urgency to perform larger randomised controlled trials as well as to systematically monitor outcomes and adverse effects of ketamine, that is currently prescribed off-label for patients in need.Declaration of interestR.M. is consulting and is Principal Investigator for Janssen trials of esketamine and is consulting for Eleusis.
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
Authors: Sledge George W. , Toi Masakazu , Neven Patrick , Sohn Joohyuk , Inoue Kenichi , Pivot Xavier B. , Burdaeva Olga Nikolaevna , Okera Meena , Masuda Norikazu , Kaufman Peter A. , Koh Han A. , Grischke Eva-Maria , Frenzel Martin , Lin Yong , Barriga Susana , Smith Ian C. , Bourayou Nawel , Llombart-Cussac Antonio 
Published: September 2018

1000 Background: Abemaciclib, an oral, selective inhibitor of CDK4 & 6, dosed on a continuous schedule, demonstrated clinical activity as monotherapy in patients (pts) with treatment refractory hormone receptor positive (HR+) metastatic breast cancer (MBC). The tolerability and activity of abemaciclib + fulvestrant (F) supported Phase 3 evaluation. Methods: MONARCH 2 is a double-blind Phase 3 trial of abemaciclib + F vs placebo (P) + F in women with HR+/HER2- advanced breast cancer. Women who progressed on (neo)adjuvant endocrine therapy (ET), ≤12 months from end of adjuvant ET, or on first line ET for MBC and who had not received chemotherapy for metastatic disease were eligible. Pts were randomized 2:1 to receive abemaciclib at 150 mg Q12H (or 200 mg prior to amendment) or P plus F (500 mg, per label) and stratified by metastatic site (visceral, bone only, or other) and resistance to prior ET (primary vs secondary). Pre/perimenopausal pts received a gonadotropin-releasing hormone agonist. The primary objective was investigator-assessed progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and other efficacy and safety endpoints. Assuming a hazard ratio (HR) of 0.703 in favor of abemaciclib + F, 378 events were needed for 90% power at one sided α=.025. Results: 669 pts were randomized to abemaciclib + F (N=446) and to P + F (N=223). 56% of pts had visceral disease, 72% had measurable disease, 25% had primary ET resistance, and 82% were postmenopausal. In the ITT population 379 PFS events were observed with a median PFS of 16.4 m for abemaciclib + F and 9.3 m for P + F (HR: 0.553; 95% CI: 0.449, 0.681, P<.0000001 by log-rank test). In pts with measurable disease, the ORR was 48.1% (3.5% complete response [CR]) for abemaciclib + F and 21.3% (0% CR) for P + F. The most frequent treatment emergent adverse events for abemaciclib + F vs P + F were diarrhea (86.4% vs 24.7%), neutropenia (46.0% vs 4.0%), nausea (45.1% vs 22.9%), and fatigue (39.9% vs 26.9%). Conclusions: Abemaciclib + fulvestrant was an effective treatment in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy with significantly improved PFS and ORR. Clinical trial information: NCT02107703.
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).
Authors: Finn Richard S. , Crown John , Lang Istvan , Boer Katalin , Bondarenko Igor , Kulyk Sergey O. , Ettl Johannes , Patel Ravindranath , Pinter Tamas , Schmidt Marcus , Shparyk Yaroslav V. , Thummala Anu , Voytko Nataliya L. , Fowst Camilla , Huang Xin , Kim Sindy , Slamon Dennis J. 
Published: September 2018

1001 Background: Preclinical data identified a synergistic role for P and hormone blockade in blocking growth of ER+ breast cancer (BC) cell lines. PALOMA-1 was an open-label phase II trial comparing progression-free survival (PFS) in patients (pts) with advanced ER+/HER2– BC treated with P+L or L alone. Median PFS increased with addition of P to L to 20.2 mos (vs 10.2 mos with L alone; HR = 0.488), with an acceptable safety profile, leading to accelerated approval by the US FDA. These results were confirmed in the phase 3 PALOMA-2 trial. At the time of the final PFS analysis, overall survival (OS) data were immature with only 61 events in both arms and a median follow-up of < 30 mos with a trend in favor of P+L vs L (37.5 vs 33.3 mos; HR = 0.813; P= 0.211). Here we present final OS results. Methods: PALOMA-1 was a 2-part study evaluating P+L in ER+/HER2– advanced BC. Part 1 enrolled postmenopausal pts with this subtype using only ER+/HER2– while Part 2 enrolled pts of this subtype additionally screened for CCND1 amplification and/or loss of p16. The primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate, OS, safety, and correlative biomarker studies. A total of 165 pts were randomized; 66 in Part 1 and 99 in Part 2. Baseline characteristics were balanced between treatment arms. In both parts, pts were randomized 1:1 to receive P+L or L alone. OS data were collected as well as post-study therapy. Results: As of Dec 2016, there were 116 OS events. Median OS was 37.5 mos (95% CI: 31.4, 47.8) with P+L vs 34.5 mos (95% CI: 27.4, 42.6) for L (HR = 0.897 [95% CI: 0.623, 1.294]; P= 0.281). Median OS was 37.5 vs 33.3 mos (HR = 0.837; P= 0.280) for Part 1 and 35.1 vs 35.7 mos (HR = 0.935; P= 0.388) for Part 2. 78.6% of pts in the P+L arm received post-study systemic therapy vs 86.4% in the L arm. More pts in the L arm received ≥3 lines of therapy (37% vs 18%). Further subgroup analyses and details on post-study therapies will be presented. Conclusions: In PALOMA-1, P+L provided a statistically non-significant trend towards an improvement in OS. Survival data from the phase III, PALOMA-2 study is awaited. Sponsor: Pfizer; Clinical trial information: NCT00721409.
New-onset congestive heart failure (CHF) and cardiovascular disease (CVD) in older colorectal cancer (CRC) survivors: A population-based study.
Authors: Kenzik Kelly , Balentine Courtney , Bhatia Smita , Williams Grant Richard 
Published: September 2018

10011 Background: CRC is primarily a disease of the elderly. The high burden of pre-existing comorbidities alone or in concert with cancer treatment place the older patients with CRC at increased risk of new-onset morbidities, specifically, CVD and CHF. However, the magnitude of risk of new-onset morbidity, and its association with pre-existing comorbidities or treatment remain unknown. Methods: Using SEER-Medicare data, we evaluated individuals diagnosed with incident stage I-III CRC at age ≥66y between 1/1/2000 and 12/31/2011 who had survived ≥2y after diagnosis (n = 57,256; 77% with colon cancer). We compared these to an age, sex-, and race-frequency matched comparison group of non-cancer Medicare patients (n = 104,731). We evaluated new-onset CHF and CVD using competing risk cumulative incidence functions and multivariable Cox regression models. Results: The median age at diagnosis was 77y (66-106y); 45% males; and 85% non-Hispanic white. Median follow-up was 8y (2-14y) from diagnosis of CRC. Treatment included surgery for 99%, chemotherapy for 31%, and radiation for 12%. New-onset morbidity: The 10y cumulative incidence of new-onset CHF and CVD were 43.6% and 58.9%, respectively. After controlling for pre-cancer comorbidities, CRC survivors were at increased risk of new-onset CHF (HR 1.29) and CVD (HR 1.74) (all p < 0.001) compared to controls. Patients receiving radiation (HR 1.29) or 5-FU+oxaliplatin (HR 1.09) were at increased risk of CVD compared to those without those therapies (p < 0.001). Pre-existing diabetes (HR 1.16) and CHF (HR 1.21) independently increased the risk of CVD (p < 0.001). While 5FU+oxaliplatin did not increase the risk of CHF independently (HR 0.97), diabetic patients treated with 5-FU+oxaliplatin were at 1.71-fold increased risk of developing CHF (p < 0.001) when compared with those without pre-existing diabetes. Conclusions: Older CRC survivors are at increased of developing CHF and CVD. Monitoring survivors with a history of exposure to 5FU+oxaliplatin or radiation, and improving management of pre-existing comorbidities may reduce the burden of long-term morbidity for older CRC survivors.
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2−) metastatic breast cancer (mBC) (TREnd trial).
Authors: Malorni Luca , Curigliano Giuseppe , Minisini Alessandro Marco , Cinieri Saverio , Tondini Carlo , Arpino Grazia , Pavesi Lorenzo , Martignetti Angelo , Criscitiello Carmen , Puglisi Fabio , Pestrin Marta , Sanna Giuseppina , Moretti Erica , Risi Emanuela , Biagioni Chiara , Boni Luca , Baldari Daniela , Buyse Marc E. , Biganzoli Laura , Di Leo Angelo 
Published: September 2018

1002 Background: P is approved for treatment of HR+/HER2− mBC combined with ET. There is paucity of clinical data of single-agent P in ET resistant pts. Pre-clinical data suggest P may partially reverse endocrine resistance, though this is yet to be tested in pts. Methods: This Phase II, open-label, multicenter study enrolled post-menopausal pts with HR+ HER2− mBC who progressed on 1 or 2 prior ETs. Pts were randomized to P (125 mg/d 3 w on/1 w off) alone or to continue their current ET (aromatase inhibitor or fulvestrant) in combination with P (same schedule as P arm). The primary endpoint was clinical benefit rate (CBR) [complete response (CR), partial response (PR) and stable disease (SD) for > 6 months (mo)]. Secondary endpoints were adverse events (AE) and additional measures of efficacy. A two-stage optimal design assessed treatment activity in each arm assuming activity as CB≥40% (α and β = 10%). Exploratory comparisons were planned for safety and efficacy endpoints. Results: 115 pts were enrolled (ITT population) 58 in the P arm and 57 in the P+ET arm. In both arms, 67% of pts had the study treatment as second line ET, 33% as third line, and about 1/3 of pts also received 1 prior chemotherapy for mBC. CBR was similar in both arms: 54% (95% CI 42 - 67%) with P+ET, and 60% (95% CI 48 -73%) with P alone. Median duration of CB was longer with P+ET (11.5 mo; 95% CI 8.6 – 17.8) than with P (6 mo; 95% CI 3.9 - 9.9) (HR 0.31, 95% CI 0.1 - 0.7, p-value 0.001, exploratory). Objective response rate (ORR; CR, PR) was 11% (95% CI 3 - 19%) and 7% (95% CI 0.4 -13%) with P+ET and P, respectively. PFS was 10.8 mo (95% CI 5.6 - 12.7) with P+ET and 6.5 mo (95% CI 5.4 - 8.5) with P alone (HR 0.69, 95% CI 0.4 - 1.1, p-value 0.13, exploratory). AEs were in line with previous data. Conclusions: Single agent P has clinical activity in ET pre-treated HR+/HER2– mBC pts. The observed increase in PFS and duration of CB with P+ET may suggest that P could reverse resistance to the prior line of ET. Translational studies are ongoing to explore potential biomarkers in this setting. Clinical trial information: NCT02549430.